Phylogenetics-innovations
The key innovation concept in
evolutionary biology has generated both tremendous interest and controversy. The idea of key traits that promote differential
evolutionary success of the lineages that bear them has an immediate and intuitive appeal. Birds, by nearly any measure, are a tremendously successful group of vertebrates and have radiated into a vast array of ecological niches that are largely inaccessible to many other taxa. It is tempting to think that a particular trait or complex of traits might underlie this seeming pattern of
evolutionary exceptionalism. In perhaps the first formal usage of the term, Miller described key innovations as adjustments to morphological and physiological traits that allow organisms to radiate within a new ecological plane, unconstrained by competitors that may have inhibited their diversification in the ancestral plane. In Miller's view, innovations would also come to characterize major taxa because
species whose ecologies spanned both adaptive zones would be negatively impacted by interactions with
species in both. Hence, gaps would develop between members of the ancestral adaptive zone and the new adaptive zone. Beginning in the 1980s, the rise of modern phylogenetic biology led to a shift in the way
evolutionary biologists conceptualized and operationalized the idea of key innovations. Became widespread, biologists increasingly recognized the significance of widespread variation in
species richness across the tree of life. The availability of phylogenies, and the desire to extract
evolutionary inferences from them, provided a catalyst for the development of sophisticated statistical tools for studying the tempo and mode of lineage diversification. These tools could be used to determine whether the disparities in
species richness observed across the tree of life could be explained by chance variation resulting from a common stochastic process, or whether it was necessary to invoke deterministic factors to explain differential diversity..
High Impact List of Articles
-
Limitless starting materials for large-scale manufacture of MSCs - what does the future hold?
Kilian Kelly
Editorial: Pharmaceutical Bioprocessing
-
Limitless starting materials for large-scale manufacture of MSCs - what does the future hold?
Kilian Kelly
Editorial: Pharmaceutical Bioprocessing
-
Cell therapies: why scale matters
Qasim A Rafiq
Editorial: Pharmaceutical Bioprocessing
-
Cell therapies: why scale matters
Qasim A Rafiq
Editorial: Pharmaceutical Bioprocessing
-
Toward genome-scale models of the Chinese hamster ovary cells: incentives, status and perspectives
Christian S Kaas, Yuzhou Fan, Dietmar Weilguny, Claus Kristensen, Helene F Kildegaard and Mikael R Andersen*
Review Article: Pharmaceutical Bioprocessing
-
Toward genome-scale models of the Chinese hamster ovary cells: incentives, status and perspectives
Christian S Kaas, Yuzhou Fan, Dietmar Weilguny, Claus Kristensen, Helene F Kildegaard and Mikael R Andersen*
Review Article: Pharmaceutical Bioprocessing
-
Molecular farming of pharmaceutical antibodies from tobacco hair roots
Jessica Thorne
News and Views: Pharmaceutical Bioprocessing
-
Molecular farming of pharmaceutical antibodies from tobacco hair roots
Jessica Thorne
News and Views: Pharmaceutical Bioprocessing
-
Applying quality by design to glycoprotein therapeutics: experimental and computational efforts of process control
Philip M Jedrzejewski, Ioscani Jimenez del Val,Karen M Polizzi and Cleo Kontoravdi
Review Article: Pharmaceutical Bioprocessing
-
Applying quality by design to glycoprotein therapeutics: experimental and computational efforts of process control
Philip M Jedrzejewski, Ioscani Jimenez del Val,Karen M Polizzi and Cleo Kontoravdi
Review Article: Pharmaceutical Bioprocessing
Relevant Topics in Clinical